David Bearss, Halia Therapeutics CEO
December 10, 2024 10:34 AM EST
R&D

Halia Ther­a­peu­tics takes NL­RP3 in­hibitor in­to fi­nal stage of Phase 2 tri­al

Katherine Lewin

News Reporter

Halia Ther­a­peu­tics is mov­ing its lead as­set in­to the sec­ond part of a mid-stage tri­al fol­low­ing ini­tial pos­i­tive da­ta in pa­tients with an ear­ly form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Health­care shake­up hits Wash­ing­ton, with cuts at CDC, NIH and oth­er agen­cies

Ex­clu­sive: Drug­mak­ers plan Trump meet­ing next week amid Wash­ing­ton health shake­ups

Ko­jin Ther­a­peu­tics shuts down, cit­ing lack of in­vestor in­ter­est and com­plex sci­ence

ARPA-H chief is out as Trump ad­min­is­tra­tion cuts health agen­cies

BioN­Tech vets raise $90M Se­ries A for bis­pe­cif­ic I&I start­up

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times